Inhibrx Biosciences, Inc. 8-K

What Happened

• Inhibrx Biosciences, Inc. (INBX) held its 2026 Annual Meeting of Stockholders on June 3, 2026 as a virtual meeting and filed an 8-K reporting the voting results (Item 5.07).
• A quorum of 11,541,232 shares (about 79% of 14,607,286 shares outstanding as of the April 7, 2026 record date) was present or represented by proxy.
• The Board’s nominees for Class II directors were elected to serve until the 2029 annual meeting:
  • Douglas G. Forsyth — For: 7,608,469; Withheld: 1,463,474; Broker non-votes: 2,469,289.
  • Kimberly Manhard — For: 9,035,097; Withheld: 36,846; Broker non-votes: 2,469,289.
• The shareholders also ratified the Audit Committee’s appointment of BDO USA, P.C. as the company’s independent registered public accounting firm for fiscal year 2026 — For: 11,510,478; Against: 30,347; Abstained: 407.

Key Details

• Meeting date: June 3, 2026 (virtual meeting). Record date: April 7, 2026.
• Shares outstanding and entitled to vote: 14,607,286; quorum present: 11,541,232 (~79%).
• Director terms: elected to serve until the 2029 Annual Meeting (or until successor qualified).
• Auditor ratification: BDO USA, P.C. approved for the fiscal year ending Dec 31, 2026.

Why It Matters

• Confirmation of the Board nominees finalizes the company’s governance lineup for the coming term, which affects oversight, strategy and shareholder representation.
• Ratifying BDO as the independent auditor provides continuity for the company’s financial reporting and audit process for fiscal 2026.
• These are routine but material corporate governance outcomes investors watch because they influence board oversight and the integrity of audited financial statements.